Plasma Neutrophil Gelatinase-Associated Lipocalin Is Useful for Predicting Mortality in Critically Ill Patients
Abstract
1. Introduction
2. Materials and Methods
3. Results
4. Discussion
5. Conclusions
Author Contributions
Funding
Institutional Review Board Statement
Informed Consent Statement
Data Availability Statement
Conflicts of Interest
References
- Zimmerman, J.E.; Kramer, A.A.; Knaus, W.A. Changes in hospital mortality for United States intensive care unit admissions from 1988 to 2012. Crit. Care 2013, 17, R81. [Google Scholar] [CrossRef]
- Vincent, J.-L.; Rello, J.; Marshall, J.K.; Silva, E.; Anzueto, A.; Martin, C.D.; Moreno, R.; Lipman, J.; Gomersall, C.; Sakr, Y.; et al. International Study of the Prevalence and Outcomes of Infection in Intensive Care Units. JAMA 2009, 302, 2323–2329. [Google Scholar] [CrossRef] [PubMed]
- Adamski, J.; Goraj, R.; Onichimowski, D.; Gawlikowska, E.; Weigl, W. The differences between two selected intensive care units located in central and northern Europe—Preliminary observation. Anaesthesiol. Intensive Ther. 2015, 47, 117–124. [Google Scholar] [CrossRef]
- Vincent, J.-L.; Moreno, R. Clinical review: Scoring systems in the critically ill. Crit. Care 2010, 14, 207. [Google Scholar] [CrossRef] [PubMed]
- Meisner, M. Biomarkers of sepsis: Clinically useful? Curr. Opin. Crit. Care 2005, 11, 473–480. [Google Scholar] [CrossRef]
- Ho, K.M.; Lee, K.Y.; Dobb, G.J.; Webb, S.A.R. C-reactive protein concentration as a predictor of in-hospital mortality after ICU discharge: A prospective cohort study. Intensive Care Med. 2007, 34, 481–487. [Google Scholar] [CrossRef] [PubMed]
- Haase, M.; Bellomo, R.; Haase-Fielitz, A. Neutrophil gelatinase-associated lipocalin. Curr. Opin. Crit. Care 2010, 16, 526–532. [Google Scholar] [CrossRef] [PubMed]
- Devarajan, P. Neutrophil gelatinase-associated lipocalin—An emerging troponin for kidney injury. Nephrol. Dial. Transplant. 2008, 23, 3737–3743. [Google Scholar] [CrossRef] [PubMed]
- Cruz, D.N.; de Cal, M.; Garzotto, F.; Perazella, M.A.; Lentini, P.; Corradi, V.; Piccinni, P.; Ronco, C. Plasma neutrophil gelatinase-associated lipocalin is an early biomarker for acute kidney injury in an adult ICU population. Intensive Care Med. 2010, 36, 444–451. [Google Scholar] [CrossRef] [PubMed]
- Khawaja, S.; Jafri, L.; Siddiqui, I.; Hashmi, M.; Ghani, F. The utility of Neutrophil Gelatinase-Associated Lipocalin (NGAL) as a marker of acute kidney injury (AKI) in critically ill patients. Biomark. Res. 2019, 7, 4. [Google Scholar] [CrossRef] [PubMed]
- Zhang, Y.; Wang, L.; Zhou, J.; Yan, J.; Wang, B.; Hu, Y.; Dong, W. The application values of urine NGAL and MEDS scores in the prognosis evaluation of patients with sepsis and acute kidney injury. Int. J. Clin. Exp. Med. 2020, 13, 2072–2078. [Google Scholar] [CrossRef]
- Shapiro, N.I.; Trzeciak, S.; Hollander, J.E.; Birkhahn, R.; Otero, R.; Osborn, T.M.; Moretti, E.; Nguyen, H.B.; Gunnerson, K.; Milzman, D.; et al. The Diagnostic Accuracy of Plasma Neutrophil Gelatinase-Associated Lipocalin in the Prediction of Acute Kidney Injury in Emergency Department Patients with Suspected Sepsis. Ann. Emerg. Med. 2010, 56, 52–59.e1. [Google Scholar] [CrossRef]
- Bagshaw, S.M.; Bennett, M.; Haase, M.; Haase-Fielitz, A.; Egi, M.; Morimatsu, H.; D’Amico, G.; Goldsmith, D.; Devarajan, P.; Bellomo, R. Plasma and urine neutrophil gelatinase-associated lipocalin in septic versus non-septic acute kidney injury in critical illness. Intensive Care Med. 2010, 36, 452–461. [Google Scholar] [CrossRef]
- Martensson, J.; Bell, M.; Xu, S.; Bottai, M.; Ravn, B.; Venge, P.; Martling, C.-R. Association of plasma neutrophil gelatinase-associated lipocalin (NGAL) with sepsis and acute kidney dysfunction. Biomarkers 2013, 18, 349–356. [Google Scholar] [CrossRef]
- Shavit, L.; Dolgoker, I.; Ivgi, H.; Assous, M.; Slotki, I. Neutrophil Gelatinase-Associated Lipocalin as a Predictor of Complications and Mortality in Patients Undergoing Non-Cardiac Major Surgery. Kidney Blood Press. Res. 2011, 34, 116–124. [Google Scholar] [CrossRef]
- Linko, R.; Pettilä, V.; Kuitunen, A.; Korhonen, A.-M.; Nisula, S.; Alila, S.; Kiviniemi, O.; Laru-Sompa, R.; Varpula, T.; Karlsson, S.; et al. Plasma neutrophil gelatinase-associated lipocalin and adverse outcome in critically ill patients with ventilatory support. Acta Anaesthesiol. Scand. 2013, 57, 855–862. [Google Scholar] [CrossRef]
- Annigeri, R.A.; Nayak, N.M.; Madhumitha, S.; Venkataraman, R.; Balasubramaian, S.; Seshadri, R.; Vadamalai, V.; Rao, B.S.; Kowdle, P.C.; Ramakrishnan, N.; et al. Clinical utility of urine neutrophil gelatinase-associated lipocalin measured at admission to predict outcomes in heterogeneous population of critically ill patients. Indian J. Nephrol. 2016, 26, 119–124. [Google Scholar] [CrossRef]
- Algethamy, H.M.; Albeladi, F.I. Urinary neutrophil gelatinase-associated lipocalin is an excellent predictor of mortality in intensive care unit patients. Saudi Med. J. 2017, 38, 706–714. [Google Scholar] [CrossRef] [PubMed]
- Nates, J.L.; Nunnally, M.; Kleinpell, R.; Blosser, S.; Goldner, J.; Birriel, B.; Fowler, C.S.; Byrum, D.; Miles, W.S.; Bailey, H.; et al. ICU Admission, Discharge, and Triage Guidelines: A Framework to Enhance Clinical Operations, Development of Institutional Policies, and Further Research. Crit. Care Med. 2016, 44, 1553–1602. [Google Scholar] [CrossRef] [PubMed]
- Khwaja, A. KDIGO Clinical Practice Guidelines for Acute Kidney Injury. Nephron Clin. Pract. 2012, 120, c179–c184. [Google Scholar] [CrossRef] [PubMed]
- Singer, M.; Deutschman, C.S.; Seymour, C.W.; Shankar-Hari, M.; Annane, D.; Bauer, M.; Bellomo, R.; Bernard, G.R.; Chiche, J.-D.; Coopersmith, C.M.; et al. The Third International Consensus Definitions for Sepsis and Septic Shock (Sepsis-3). JAMA 2016, 315, 801–810. [Google Scholar] [CrossRef]
- Haase, M.; Bellomo, R.; Devarajan, P.; Schlattmann, P.; Haase-Fielitz, A.; NGAL Meta-Analysis Investigator Group. Accuracy of Neutrophil Gelatinase-Associated Lipocalin (NGAL) in Diagnosis and Prognosis in Acute Kidney Injury: A Systematic Review and Meta-analysis. Am. J. Kidney Dis. 2009, 54, 1012–1024. [Google Scholar] [CrossRef] [PubMed]
- Hjortrup, P.B.; Haase, N.; Wetterslev, M.; Perner, A. Clinical review: Predictive value of neutrophil gelatinase-associated lipocalin for acute kidney injury in intensive care patients. Crit. Care 2013, 17, 211. [Google Scholar] [CrossRef] [PubMed]
- Mahmoodpoor, A.; Hamishehkar, H.; Fattahi, V.; Sanaie, S.; Arora, P.; Nader, N.D. Urinary versus plasma neutrophil gelatinase-associated lipocalin (NGAL) as a predictor of mortality for acute kidney injury in intensive care unit patients. J. Clin. Anesth. 2018, 44, 12–17. [Google Scholar] [CrossRef] [PubMed]
- Hang, C.-C.; Yang, J.; Wang, S.; Li, C.-S.; Tang, Z.-R. Evaluation of serum neutrophil gelatinase-associated lipocalin in predicting acute kidney injury in critically ill patients. J. Int. Med. Res. 2017, 45, 1231–1244. [Google Scholar] [CrossRef]
- Koyner, J.L.; Bennett, M.R.; Worcester, E.M.; Ma, Q.; Raman, J.; Jeevanandam, V.; Kasza, K.E.; O’Connor, M.F.; Konczal, D.J.; Trevino, S.; et al. Urinary cystatin C as an early biomarker of acute kidney injury following adult cardiothoracic surgery. Kidney Int. 2008, 74, 1059–1069. [Google Scholar] [CrossRef]
- Silvestre, J.; Povoa, P.; Coelho, L.; Almeida, E.; Moreira, P.; Fernandes, A.; Mealha, R.; Sabino, H. Is C-reactive protein a good prognostic marker in septic patients? Intensive Care Med. 2009, 35, 909–913. [Google Scholar] [CrossRef]
- Meisner, M.; Adina, H.; Schmidt, J. Correlation of procalcitonin and C-reactive protein to inflammation, complications, and outcome during the intensive care unit course of multiple-trauma patients. Crit. Care 2006, 10, R1. [Google Scholar] [CrossRef]
- Miguel-Bayarri, V.; Casanoves-Laparra, E.; Pallás-Beneyto, L.; Sancho-Chinesta, S.; Martín-Osorio, L.; Tormo-Calandin, C.; Bautista-Rentero, D. Prognostic value of the biomarkers procalcitonin, interleukin-6 and C-reactive protein in severe sepsis. Med. Intensiva 2012, 36, 556–562. [Google Scholar] [CrossRef]
- Gradel, K.O.; Jensen, T.G.; Kolmos, H.J.; Pedersen, C.; Vinholt, P.J.; Lassen, A.T. Does C-reactive protein independently predict mortality in adult community-acquired bacteremia patients with known sepsis severity? APMIS 2012, 121, 835–842. [Google Scholar] [CrossRef]
- Oberhoffer, M.; Vogelsang, H.; Rußwurm, S.; Hartung, T.; Reinhart, K. Outcome Prediction by Traditional and New Markers of Inflammation in Patients with Sepsis. Clin. Chem. Lab. Med. 1999, 37, 363–368. [Google Scholar] [CrossRef]
- Park, J.E.; Chung, K.S.; Song, J.H.; Kim, S.Y.; Kim, E.Y.; Jung, J.Y.; Kang, Y.A.; Park, M.S.; Kim, Y.S.; Chang, J.; et al. The C-Reactive Protein/Albumin Ratio as a Predictor of Mortality in Critically Ill Patients. J. Clin. Med. 2018, 7, 333. [Google Scholar] [CrossRef] [PubMed]
- Al-Subaie, N.; Reynolds, T.; Myers, A.; Sunderland, R.; Rhodes, A.; Grounds, R.M.; Hall, G.M. C-reactive protein as a predictor of outcome after discharge from the intensive care: A prospective observational study. Br. J. Anaesth. 2010, 105, 318–325. [Google Scholar] [CrossRef] [PubMed]
- Kruse, J.A.; Thill-Baharozian, M.C.; Carlson, R.W. Comparison of Clinical Assessment with APACHE II for Predicting Mortality Risk in Patients Admitted to a Medical Intensive Care Unit. JAMA 1988, 260, 1739–1742. [Google Scholar] [CrossRef] [PubMed]
- Knaus, W.A.; Zimmerman, J.E.; Wagner, D.P.; Draper, E.A.; Lawrence, D.E. APACHE—Acute Physiology and Chronic Health Evaluation: A physiologically based classification system. Crit. Care Med. 1981, 9, 591–597. [Google Scholar] [CrossRef] [PubMed]
- Niewiński, G.; Starczewska, M.H.; Kański, A. Prognostic scoring systems for mortality in intensive care units—The APACHE model. Anaesthesiol. Intensive Ther. 2014, 46, 46–49. [Google Scholar] [CrossRef]
Variable | Value | ICU | In-Hospital | ||
---|---|---|---|---|---|
Survivors | Non-Survivors | Survivors | Non-Survivors | ||
Age, years (median, IQR) | 59 (43–67) | 50 (39–63) | 72 (61–82) * | 50 (37–64) | 66 (60–81) * |
Male gender, n (%) | 27 (43) | 9 (33) | 18 (67) | 10 (37) | 17 (63) |
APACHE II score (median, IQR) | 18 (12–23) | 14 (9–18) | 23 (21–28) * | 14 (9–18) | 23 (20–28) * |
ICU length of stay, day (median, IQR) | 9 (4–21) | 9 (4–16) | 10 (4–29) | - | - |
Hospitalization category, n (%) | |||||
Medical | 32 (51) | 25 (78) | 7(21) * | 24 (75) | 8 (25) * |
Surgical | 30 (49) | 15 (50) | 15 (50) | 14 (46) | 16 (53) |
Sepsis, n (%) | 24 (38) | 11 (35) | 13 (65) * | 10 (42) | 14 (58) * |
Acute kidney injury, n (%) | 15 (24) | 7 (47) | 8 (53) | 5 (33) | 10 (67) * |
Vasopressor use, n (%) | 39 (63) | 19 (49) | 20 (51) * | 17 (44) | 22 (56) * |
Mechanical ventilation, n (%) | 55 (89) | 33 (60) | 22 (40) | 31 (56) | 24 (44) |
Renal replacement therapy, n (%) | 7 (11) | 2 (28) | 5 (72) * | 1 (14) | 6 (86) * |
Variable | Values | ICU | In-Hospital | ||
---|---|---|---|---|---|
Survivors | Non-Survivors | Survivors | Non-Survivors | ||
NGAL (ng/mL) | 142.5 (65.62–298.29) | 88.8 (45–183) | 297.0 (102–339) * | 88.8 (48–150) | 279.4 (116–326) * |
Creatinine (mg/dL) | 1.08 (0.82–1.61) | 0.89 (0.77–1.22) | 1.52 (1.21–2.91) * | 0.89 (0.78–1.18) | 1.83 (1.1–3.42) * |
CRP (mg/L) | 70.5 (12.84–165.96) | 27.8 (5.63–149) | 146.6 (65.5–274.8) * | 18.54 (5.57–145) | 146.6 (73.6–278.1) * |
Lactate (mmol/L) | 2.1 (1.20–3.10) | 1.75 (1–2.85) | 2.45 (1.5–3.4) * | 1.6 (1–2.8) | 2.45 (1.6–3.5) * |
ICU | In-Hospital | |||
---|---|---|---|---|
NGAL (ng/mL) | Survivors (n = 40) | Non-Survivors (n = 22) | Survivors | Non-Survivors |
Day 1 | 88 (45–183) | 297 (102–339) * | 88.8 (48–150) | 279.4 (116–326) * |
Day 2 | 131 (61–274) | 251 (151–360) * | 131.4 (63.5–188.4) | 283.7 (149–360) * |
Day 3 | 111 (68–248) | 271 (213–354) * | 102.6 (68.4–173) | 297 (224–373.6) * |
Day 4 | 75 (66–131) | 250 (142–349) * | 91.2 (64.6–162) | 239 (130–348) * |
Day 1 | Day 2 | Day 3 | Day 4 | |
---|---|---|---|---|
CRP (mg/L) | R = 0.774 p < 0.0001 | R = 0.589 p < 0.0001 | R = 0.269 p = 0.1755 | R = 0.214 p = 0.2946 |
Creatinine (mg/dL) | R = 0.517 p < 0.0001 | R = 0.543 p = 0.0001 | R = 0.733 p < 0.0001 | R = 0.857 p < 0.0001 |
Lactate (mmol/L) | R = 0.226 p = 0.1038 | R = 0.430 p = 0.0032 | R = 0.396 p = 0.0335 | R = 0.367 p = 0.0649 |
APACHE II (points) | R = 0.309 p = 0.0195 | R = 0.256 p = 0.0726 | R = 0.322 p = 0.0772 | R = 0.518 p = 0.0057 |
Renal Replacement Therapy (−) | Renal Replacement Therapy (+) | |
---|---|---|
NGAL day 1 (ng/mL) | 102.7 (64.3–281.7) | 279.4 (235.8–318.6) * |
NGAL day 2 (ng/mL) | 151.5 (72.2–282.6) | 316.5 (186.5–327.4) |
NGAL day 3 (ng/mL) | 145.8 (76.4–256.1) | 310.2 (229.4–368.8) * |
NGAL day 4 (ng/mL) | 116.3 (66.4–227.8) | 250.4 (200.6–357.7) * |
CRP day 1 (mg/L) | 45.2 (9.4–158) | 238 (61.3–348) * |
CRP day 2 (mg/L) | 75.6 (34.4–168.7) | 268 (76.2–357.5) |
CRP day 3 (mg/L) | 92.5 (42.6–178.1) | 192 (77–290.2) |
CRP day 4 (mg/L) | 104.3 (57–170.6) | 145.6 (64.3–189) |
Publisher’s Note: MDPI stays neutral with regard to jurisdictional claims in published maps and institutional affiliations. |
© 2021 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
Share and Cite
Duda, I.; Krzych, Ł. Plasma Neutrophil Gelatinase-Associated Lipocalin Is Useful for Predicting Mortality in Critically Ill Patients. J. Clin. Med. 2021, 10, 2576. https://doi.org/10.3390/jcm10122576
Duda I, Krzych Ł. Plasma Neutrophil Gelatinase-Associated Lipocalin Is Useful for Predicting Mortality in Critically Ill Patients. Journal of Clinical Medicine. 2021; 10(12):2576. https://doi.org/10.3390/jcm10122576
Chicago/Turabian StyleDuda, Izabela, and Łukasz Krzych. 2021. "Plasma Neutrophil Gelatinase-Associated Lipocalin Is Useful for Predicting Mortality in Critically Ill Patients" Journal of Clinical Medicine 10, no. 12: 2576. https://doi.org/10.3390/jcm10122576
APA StyleDuda, I., & Krzych, Ł. (2021). Plasma Neutrophil Gelatinase-Associated Lipocalin Is Useful for Predicting Mortality in Critically Ill Patients. Journal of Clinical Medicine, 10(12), 2576. https://doi.org/10.3390/jcm10122576